Pharma Mar S.A. | Key People and Executives
José Maria Fernández de Sousa-Faro
Executive Chairman, President & CEO
José Francisco Leyte Verdejo
Director
Montserrat Andrade Detrell
Director
José Félix Pérez-Orive Carceller
External Director
Pedro Fernández Puentes
Executive Vice Chairman
Jaime Zurita Sáenz de Navarrete
Independent Director
Carlos Solchaga Catalán
Independent Director
Eduardo Serra Rexach
Independent Director
Ana Palacio del Vallelersundi
Independent Director
José Maria Fernández de Sousa-Faro
Executive Chairman, President & CEO
Pascal M. Besman
Chief Operating Officer
Maria Luisa de Francia Caballero
Chief Financial Officer
Nadia Badri
Vice President-Medical Affairs
Arturo Soto Matos-Pita
Director-Clinical Development
Carmen Cuevas Marchante
Director-Research & Development
Belén Sopesén Veramendi
Director-Market Research & Development
Heiner Pieper
Vice President-Business Development & Licensing
Luis Mora Capitán
Managing Director-Oncology Business Unit
José Luis Ortega
Director-Quality Unit
Elena Calleja Crespo
Finance Director
José Francisco Leyte Verdejo
Director
Montserrat Andrade Detrell
Director
José Félix Pérez-Orive Carceller
External Director
Pedro Fernández Puentes
Executive Vice Chairman
Juan Nogués Ortuño
Director-International Marketing & Sales
Juan Carlos Villalón Gomez
Internal Auditor
Alfonso Ortín
Communications Director
José Luis Moreno Martinez-Losa
Director-Investor Relations & Capital Markets
Luis Rupérez Cuenca
Director-Human Resources & Information Technology
Sebastian Cuenca Miranda
Secretary & General Counsel
Ana Belén Irigaray Huarte
Director-Regulatory Affairs
Jaime Zurita Sáenz de Navarrete
Independent Director
Carlos Solchaga Catalán
Independent Director
Eduardo Serra Rexach
Independent Director
Ana Palacio del Vallelersundi
Independent Director
| Address |
Avenida de los Reyes, 1
Colmenar Viejo Madrid 28770
Spain
|
|
Employees
|
- |
| Website |
http://www.pharmamar.es |
| Updated |
07/08/2019 |
| Pharma Mar SA is a biopharmaceutical holding company, which engages in discovery and development of innovative marine-derived anticancer drugs. It operates through the following segments: Oncology, Diagnostics, RNAi, and Consumer Chemicals. The Oncology segment encompasses the Group undertakings whose object is to research, develop and market anti-tumour drugs. |
